A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study

Introduction Anti-vascular endothelial growth factor therapy has revolutionised the treatment of neovascular age-related macular degeneration (nAMD). However, some patients face recurrent and persistent disease activity despite ongoing treatment. Faricimab (trade name: Vabysmo) is a recently approve...

Full description

Bibliographic Details

Published in:	BMJ Open Ophthalmology
Main Authors:	Samantha Fraser-Bell, Thomas Hong, Andrew A Chang, Hemal Mehta, Gemmy C M Cheung, Geoffrey K Broadhead, Long T Phan, John H Chang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-10-01
Online Access:	https://bmjophth.bmj.com/content/10/1/e002326.full